RABIES HUMAN MONOCLONAL ANTIBODY

Rabies human monoclonal antibodies are a category of immune globulins.

Rabies human monoclonal antibodies (RMAbs) primarily provide immediate passive immunity to individuals exposed to the rabies virus, particularly in high-risk situations.

Rabies human monoclonal antibodies are primarily administered intramuscularly, typically at the site of the potential rabies exposure. The best route of administration depends on the individual's needs and preferences, but oral administration is typically the most convenient.

Common side effects of Rabies human monoclonal antibodies may include localized reactions at the injection site, such as pain, swelling, redness, and a low-grade fever. Serious side effects are rare but may involve severe allergic reactions (anaphylaxis) that can result in symptoms like difficulty breathing, facial or throat swelling, hives, and a drop in blood pressure.

Rabies human monoclonal antibodies may risk severe allergic reactions, including anaphylaxis, which can be life-threatening. Some individuals may experience a mild increase in body temperature (low-grade fever) as a common side effect.

Assess the patient's history of allergies, particularly any components of Rabies human monoclonal antibodies or previous reactions to monoclonal antibody therapies. Administer it promptly after potential rabies exposure, as delay can reduce their effectiveness.

Confirm the patient has no allergy to rabies human monoclonal antibody or its components, and has not previously experienced adverse reactions to similar treatments. Administer promptly following potential rabies exposure, as delays reduce efficacy. Evaluate the patient's clinical status carefully, particularly immune competence, as immunosuppression may compromise treatment response. Weigh risks and benefits carefully when considering use during pregnancy or lactation. Monitor the patient closely during and after administration, especially if other medical conditions are present. Establish whether the patient has received prior rabies vaccination, as this agent is typically used concurrently with rabies vaccine series. In cases of multiple potential rabies exposures, consider administering additional doses. For paediatric or elderly patients, consider age and body weight when determining dosage.

Sudarshan MK. World Health Organization 2018 Guidelines on Rabies Prophylaxis: Contentious Issues. Pediatr Inf Dis 2019;1(4):154–156, https://www.pidjournal.com/doi/PID/pdf/10.5005/jp-journals-10081-1226 Thomas Moulenat et al., Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019, Trop. Med. Infect. Dis., 2020, 5, 40, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157209/pdf/tropicalmed-05-00040.pdf Serum Institute of India Pvt Ltd, [Revised on 2021] [Accessed on 10th Oct 2023], https://www.seruminstitute.com/product_ind_rabishield.php Anwith, H S & Ravish, Haradanahalli & Ashwathnarayana, Doddabele, Safety of new indigenous human Rabies Monoclonal Antibody (RMAb) for Post Exposure Prophylaxis, Indian Journal of Community Health, 2018, 30, 196-201, https://www.researchgate.net/publication/328743661_Safety_of_new_indigenous_human_Rabies_Monoclonal_Antibody_RMAb_for_Post_Exposure_Prophylaxis_Corresponding_Author_Citation_Article_Cycle